Locally Advanced Head & Neck Squamous Cell Carcinoma research hub
3 indexed studies · 3 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma
This study looks at a new way to treat advanced head and neck cancer in older patients not suitable for standard chemotherapy. It combines a special gel (NBTXR3) with usual radiotherapy, sometimes with another drug (Cetuximab, also known as Erbitux), to see if it helps patients live longer without their cancer getting worse.
Czechia · Greece · Germany - recruitingPhase III
JNJ-90301900 (NBTXR3) activated by radiotherapy with or without cetuximab in LA-HNSCC
This study looks at a new treatment called JNJ-90301900 with radiotherapy, sometimes with another drug called cetuximab. It's for older patients with a type of head and neck cancer who can't have standard chemotherapy.
United Kingdom · Austria · Belgium - recruitingPHASE3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
This study is testing a new medicine, volrustomig, for people with a type of head and neck cancer that hasn't spread and wasn't removed by surgery. It aims to see if volrustomig helps prevent the cancer from coming back after standard treatment like chemotherapy and radiotherapy.
United States · Austria · Belgium